Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
MayzentⓇ - S1P1,5 receptor modulator
NCT04926818 NEOS (CBAF312D2301)
Indication
Phase
Multiple sclerosis, pediatrics
Phase 3
Patients
180
Primary
Outcome
Annualized relapse rate (ARR) in target pediatric participants
Conclusions
Neuroscience
Measures
Arms
Intervention
Target
Patients
Arm 1: Experimental ofatumumab - 20 mg injection/ placebo
Arm 2: Experimental siponimod - 0.5 mg, 1 mg or 2 mg/ placebo
Arm 3: Active Comparator fingolimod - 0.5 mg or 0.25 mg/ placebo
Children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS).
The targeted enrollment is 180 participants with multiple sclerosis which will
include at least 5 participants with body weight (BW) ≤40 kg and at least 5
participants with age 10 to 12 years in each of the ofatumumab and siponimod
arms. There is a minimum 6 month follow up period for all participants (core
and extension). Total duration of the study could be up to 7 years.
2026
Readout
Milestone(s)
Publication
TBD
61 Investor Relations | Q2 2023 Results
Appendix
Innovation: Clinical trials
Oncology
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation